MERCK & CO., INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131.1 USD | +0.28% |
|
+0.96% | +19.90% |
| 06-18 | Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon... |  |
| 06-18 | Merck: FDA approves Capvaxive pneumococcal vaccine | CF |
Presenter SpeechChris Shibutani (Analysts)On behalf of the entire Goldman Sachs Healthcare Res...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
30/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
130.7
USD
Average target price
142.7
USD
Spread / Average Target
+9.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.90% | 331B | |
| +51.63% | 796B | |
| +40.71% | 628B | |
| -5.10% | 358B | |
| +9.95% | 301B | |
| +17.43% | 244B | |
| +3.89% | 228B | |
| +12.90% | 214B | |
| +6.99% | 165B | |
| -3.65% | 157B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Transcript : Merck & Co., Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10
